Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV;Mise en oeuvre de la prophylaxie par le co-trimoxazole et du traitement préventif par l'isoniazide chez les personnes vivant avec le VIH

Bulletin of the World Health Organization

Volumn 88, Issue 4, 2010, Pages 253-259

  Date, Anand A ^a   Vitoria, Marco ^b   Granich, Reuben ^b   Banda, Mazuwa ^b   Fox, Mayada Youssef ^b   Gilks, Charlie ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ISONIAZID;

DISEASE TREATMENT; DRUG PRESCRIBING; DRUG USER; HEALTH POLICY; HUMAN IMMUNODEFICIENCY VIRUS; POLICY DEVELOPMENT; POLICY IMPLEMENTATION; QUESTIONNAIRE SURVEY; WORLD HEALTH ORGANIZATION;

ARTICLE; CHEMOPROPHYLAXIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG RESISTANCE; E-MAIL; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; TREATMENT INDICATION; TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; ISONIAZID; PHYSICIAN'S PRACTICE PATTERNS; PUBLIC POLICY; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; WORLD HEALTH ORGANIZATION;

EID: 77950788938     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.09.066522     Document Type: Article

References (41)

1. Report on the global AIDS epidemic. Geneva: UNAIDS; 2008. Available from: http://data.unaids.org/pub/GlobalReport/2008/JC1510_2008GlobalReport_en. zip [accessed 8 October 2009].
2. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization/United Nation's Joint Programme on HIV/AIDS/United Nations Children's Fund; 2008. Available from: http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf [accessed 8 October 2009].
3. United States President's Emergency Plan for AIDS Relief [Internet site]. Available from: http://www.pepfar.gov/ [accessed 8 October 2009].
4. Global Fund to Fight AIDS, Tuberculosis and Malaria [Internet site]. Available from: http://www.theglobalfund.org/en/ [accessed 8 October 2009].
5. The Cochrane Collaborative Review Group on HIV Infection and AIDS. Evidence assessment: strategies for HIV/AIDS prevention, treatment and care. San Francisco: University of California, San Francisco, Institute for Global Health; 2004.
6. Jones JL, Hanson DL, Dworkin MS, Alderton DL, Fleming PL, Kaplan JE, et al. Surveillance for AIDS-defining opportunistic illness, 1992-1997. MMWR CDC Surveill Summ 1999; 48: 1-22. PMID: 12412613.
7. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A, et al. Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008; 337: a257. doi: 10.1136/bmj.a257 PMID: 18617486.
8. Mulenga V, Ford D, Walker A, Mwenya D, Mwansa J, Sinyinza F, et al. Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS 2007; 21: 77-84. doi: 10.1097/QAD.0b013e3280114ed7 PMID: 17148971.
9. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al., Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups, et al. Mortality of HIV-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-24. doi: 10.1016/S0140-6736(06)68337-2 PMID: 16530575.
10. Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, Eiger O, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 2007; 46: 56-61. PMID: 17972365.
11. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, Maurice C, et al. Efficacy of trimethoprimsulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-75. doi: 10.1016/S0140-6736(99)03465-0 PMID: 10232312.
12. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999; 353: 1463-8. doi: 10.1016/S0140-6736(98)07399-1 PMID: 10232311.
13. Badri M, Maartens G, Wood R, Ehrlich R. Co-trimoxazole and HIV-1 infection. Lancet 1999; 354: 334-5. doi: 10.1016/S0140-6736(05)75237-5 PMID: 10440331.
14. Zachariah R, Spielmann M, Chinji C, Gomani P, Arendt V, Hargreaves N, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003; 17: 1053-61. doi: 10.1097/00002030-200305020-00015 PMID: 12700456.
15. Zachariah R, Harries A, Arendt V, Wennig R, Schneider S, Spielmann M, et al. Compliance to cotrimoxazole for the prevention of opportunistic infections in HIV infected tuberculosis patients in Thyolo, Malawi. Int J Tuberc Lung Dis 2001; 5: 843-6. PMID: 11573896.
16. Mwaungulu FB, Floyd S, Crampin AC, Kasimba S, Malema S, Kanyongoloka H, et al. Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi. Bull World Health Organ 2004; 82: 354-63. PMID: 15298226.
17. Chimzizi R, Gausi F, Bwanali A, Mbalume D, Teck R, Gomani P, et al. Voluntary counselling, HIV testing and adjunctive cotrimoxazole are associated with improved TB treatment outcomes under routine conditions in Thyolo District, Malawi. Int J Tuberc Lung Dis 2004; 8: 579-85. PMID: 15137534.
18. Chimzizi RB, Harries AD, Manda E, Khonyongwa A, Salaniponi FM. Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. Int J Tuberc Lung Dis 2004; 8: 938-44. PMID: 15305474.
19. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364: 1428-34. doi: 10.1016/S0140-6736(04)17225-5 PMID: 15488218.
20. Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV. Cochrane Database Syst Rev 2003:CD003108. PMID: 12917946.
21. Grimwade K, Swingler GH. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection. Cochrane Database Syst Rev 2006:CD003508. PMID: 16437457.
22. Grimwade K, Sturm A, Nunn A, Mbatha D, Zungu D, Gilks C. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005; 19: 163-8. doi: 10.1097/00002030-200501280-00008 PMID: 15668541.
23. Chintu C, Bhat G, Walker A, Mulenga V, Sinyinza F, Lishimpi K, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364: 1865-71. doi: 10.1016/S0140-6736(04)17442-4 PMID: 15555666.
24. Creese A, Floyd K, Alban A, Guinness L. Cost effectiveness of HIV/AIDS interventions in Africa; a systematic review of the evidence. Lancet 2002; 359: 1635-43. doi: 10.1016/S0140-6736(02)08595-1 PMID: 12020523.
25. Watera C, Todd J, Muwonge R, Whitworth J, Nakiyingi-Miiro J, Brink A, et al. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/ AIDS clinic in Uganda. J Acquir Immune Defic Syndr 2006; 42: 373-8. PMID: 16810124.
26. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006; 355: 1141-53. doi: 10.1056/NEJMsa060247 PMID: 16971720.
27. Guidelines on co-trimoxazole prophylaxis for HIV infections among children, adolescents and adults in resource-limited settings: recommendations for a public health approach. Geneva: World Health Organization; 2006.
28. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337: 801-8. doi: 10.1056/NEJM199709183371201 PMID: 9295239.
29. de Pinho AM, Santoro-Lopes G, Harrison LH, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS 2001; 15: 2129-35. doi: 10.1097/00002030-200111090-00008 PMID: 11684932.
30. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998; 351: 786-92. doi: 10.1016/S0140-6736(97)06532-X PMID: 9519950.
31. Pape JW, Jean SS, Ho JL, Hafner A, Johnson W. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993; 342: 268-72. doi: 10.1016/0140-6736(93)91817-6 PMID: 8101302.
32. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala B, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-57. doi: 10.1097/00002030-199818000-00014 PMID: 9875583.
33. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 1997; 337: 315-20. doi: 10.1056/NEJM199707313370505 PMID: 9233868.
34. Bucher HC, Griffith LE, Guyat GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-7. doi: 10.1097/00002030-199903110-00009 PMID: 10197379.
35. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database Syst Rev 2004:CD000171. PMID: 14973947.
36. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-8. doi: 10.1097/QAD.0b013e328216f441 PMID: 17589190.
37. Policy statement on preventive therapy against tuberculosis in people living with HIV. Geneva: World Health Organization; 1998 (WHO/TB/98.255).
38. Consensus statement of the core group of TB/HIV Working Group of STOP TB partnership. Geneva: Stop TB partnership. Available from: http://www.stoptb.org/wg/tb_hiv/assets/documents/IPT%20Consensus%20State ment%20TB%20HIV%20Core%20Group.pdf [accessed 8 October 2009].
39. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings. Geneva: World Health Organization; 2008. Available from: http://www.who.int/hiv/pub/prev_care/OMS_EPP_AFF_en.pdf [accessed 8 October 2009].
40. Global tuberculosis control surveillance, planning and financing. Geneva: World Health Organization; 2009 (WHO/TB/2009.411). Available from: http://www.who.int/tb/publications/global_report/2009/pdf/full_report.pd f. [accessed 8 October 2009].
41. Three I's meeting: intensified TB case finding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Geneva: World Health Organization; 2008. Available from: http://www.who.int/hiv/pub/meetingreports/WHO_3Is_meeting_report.pdf [accessed 8 October 2009].